Patient demographics and baseline disease characteristics
| Intention-to-treat population* | Placebo n=157 | Atacicept 75 mg n=159 | Atacicept 150 mg n=145 |
|---|---|---|---|
| Mean age (range), years | 39.0 (20–79) | 39.1 (16–75) | 39.0 (17–69) |
| Female, n (%) | 148 (94.3) | 148 (93.1) | 134 (92.4) |
| Race, n (%) | |||
| White | 114 (72.6) | 114 (71.7) | 102 (70.3) |
| Black | 3 (1.9) | 5 (3.1) | 2 (1.4) |
| Asian | 30 (19.1) | 29 (18.2) | 31 (21.4) |
| Other | 10 (6.4) | 11 (6.9) | 10 (6.9) |
| Disease severity at screening, n (%) | |||
| ≥1 BILAG A | 31 (19.7) | 32 (20.1) | 31 (21.4) |
| Only BILAG B | 126 (80.3) | 127 (79.9) | 114 (78.6) |
| Potential completer population | Placebo n=81 | Atacicept 75 mg n=84 | Atacicept 150 mg n=81 |
| Mean age (range), years | 37.1 (20–63) | 39.2 (16–75) | 38.5 (18–69) |
| Female, n (%) | 76 (93.8) | 79 (94.0) | 73 (90.1) |
| Race, n (%) | |||
| White | 52 (64.2) | 53 (63.1) | 53 (65.4) |
| Black | 1 (1.2) | 3 (3.6) | 1 (1.2) |
| Asian | 19 (23.5) | 18 (21.4) | 21 (25.9) |
| Other | 9 (11.1) | 10 (11.9) | 6 (7.4) |
| Disease severity at screening, n (%) | |||
| ≥1 BILAG A | 18 (22.2) | 19 (22.6) | 18 (22.2) |
| Only BILAG B | 63 (77.8) | 65 (77.4) | 63 (77.8) |
*Patient demographics were similar in the intention-to-treat and modified intention-to-treat populations.
BILAG, British Isles Lupus Assessment Group.